Literature DB >> 23609324

Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma.

Guorong Li1, Grégory Badin, An Zhao, Anne Gentil-Perret, Jacques Tostain, Michel Péoc'h, Marc Gigante.   

Abstract

INTRODUCTION: The expression of CXCR4 is implicated in the metastatic dissemination of different cancers. The information on its prognostic value has been very limited in clear cell renal cell carcinoma (ccRCC). Our objective was to explore the prognostic value of CXCR4 in ccRCC.
MATERIALS AND METHODS: 104 patients with a ccRCC were studied. There were 69 men and 35 women with an average age of 64.5 years old (range: 34-86 years). The CXCR4 expression was evaluated by immunohistochemistry. The follow-up varied from 12 to 184 months with a mean of 79.5 months. Kaplan-Meier with a log rank test was performed to compare overall survival and cancer-specific survival after surgery. Univariate and multivariate analyses were performed according to the Cox regression model.
RESULTS: CXCR4 expression was found in 68/104 (65.4%) of tumor samples. CXCR4 expression was located in the nucleus in 55/68 (80.8%) cases while cytoplasm or membrane location was found in 13/68 (19.2%) cases. High expression was found in 25/68 (36.8%) cases. During follow-up, 39 patients died, of which 26 died of cancer. Kaplan-Meier analysis revealed that a high expression of CXCR4 was associated with a reduced overall survival (p=0.017) and cancer-specific survival (p=0.022). Univariate analysis indicated that a high expression of CXCR4 was a significant factor for a poorer overall survival (p=0.020) and cancer-specific survival (p=0.027). By multivariate analysis, a high expression of CXCR4 appeared to be an independent factor of overall survival (p=0.024) and cancer-specific survival (p=0.028).
CONCLUSION: This study suggested that a high CXCR4 expression was correlated with a worse outcome for ccRCC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609324     DOI: 10.14670/HH-28.1217

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  10 in total

Review 1.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

2.  A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.

Authors:  A M Nowicka; I Häuselmann; L Borsig; S Bolduan; M Schindler; P Schraml; M Heikenwalder; H Moch
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

3.  Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway.

Authors:  Guanghui Hu; Junjie Ma; Jin Zhang; Yonghui Chen; Huan Liu; Yiran Huang; Junhua Zheng; Yunfei Xu; Wei Xue; Wei Zhai
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 12.910

Review 4.  Biology of renal tumour cancer stem cells applied in medicine.

Authors:  Damian Matak; Lukasz Szymanski; Cezary Szczylik; Rafal Sledziewski; Fei Lian; Ewa Bartnik; Anna Sobocinska; Anna M Czarnecka
Journal:  Contemp Oncol (Pozn)       Date:  2015

Review 5.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10

Review 6.  Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.

Authors:  Yuefeng Du; Qingzhi Long; Bing Guan; Lijun Mu
Journal:  Dis Markers       Date:  2015-10-07       Impact factor: 3.434

7.  Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.

Authors:  S Bihorel; E Raddad; J Fiedler-Kelly; J R Stille; J Hing; E Ludwig
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-09-22

8.  Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.

Authors:  Bo Cheng; Guosheng Yang; Rui Jiang; Yong Cheng; Haifan Yang; Lijun Pei; Xiaofu Qiu
Journal:  Oncotarget       Date:  2016-10-04

Review 9.  Renal Cancer Stem Cells: Characterization and Targeted Therapies.

Authors:  Anna Julie Peired; Alessandro Sisti; Paola Romagnani
Journal:  Stem Cells Int       Date:  2016-05-15       Impact factor: 5.443

10.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.